🚀 VC round data is live in beta, check it out!
Genomma Lab Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genomma Lab and similar public comparables like Procter & Gamble Health, Sido Muncul, Mega Lifesciences, Jamieson Wellness and more.
Genomma Lab Overview
About Genomma Lab
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Founded
1996
HQ
Employees
1.7K
Website
Financials (LTM)
EV
$1B
Genomma Lab Financials
Genomma Lab reported last 12-month revenue of $1B and EBITDA of $241M.
In the same LTM period, Genomma Lab generated $642M in gross profit, $241M in EBITDA, and $102M in net income.
Revenue (LTM)
Genomma Lab P&L
In the most recent fiscal year, Genomma Lab reported revenue of $1B and EBITDA of $243M.
Genomma Lab expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $642M | XXX | $608M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $241M | XXX | $243M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $102M | XXX | $98M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $94M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Genomma Lab Stock Performance
Genomma Lab has current market cap of $953M, and enterprise value of $1B.
Market Cap Evolution
Genomma Lab's stock price is $0.98.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $953M | 0.0% | XXX | XXX | XXX | $0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenomma Lab Valuation Multiples
Genomma Lab trades at 1.2x EV/Revenue multiple, and 5.1x EV/EBITDA.
EV / Revenue (LTM)
Genomma Lab Financial Valuation Multiples
As of April 2, 2026, Genomma Lab has market cap of $953M and EV of $1B.
Equity research analysts estimate Genomma Lab's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genomma Lab has a P/E ratio of 9.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $953M | XXX | $953M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 5.1x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBIT | 5.5x | XXX | 5.5x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | 2.0x | XXX | XXX | XXX |
| P/E | 9.3x | XXX | 9.8x | XXX | XXX | XXX |
| EV/FCF | 16.9x | XXX | 10.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genomma Lab Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Genomma Lab Margins & Growth Rates
Genomma Lab's revenue in the last 12 month grew by 1%.
Genomma Lab's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.
Genomma Lab's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genomma Lab's rule of X is 33% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Genomma Lab Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | (0%) | XXX | (3%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 38% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Genomma Lab Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Sido Muncul | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Jamieson Wellness | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaNutra | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genomma Lab M&A Activity
Genomma Lab acquired XXX companies to date.
Last acquisition by Genomma Lab was on XXXXXXXX, XXXXX. Genomma Lab acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Genomma Lab
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGenomma Lab Investment Activity
Genomma Lab invested in XXX companies to date.
Genomma Lab made its latest investment on XXXXXXXX, XXXXX. Genomma Lab invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Genomma Lab
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genomma Lab
| When was Genomma Lab founded? | Genomma Lab was founded in 1996. |
| Where is Genomma Lab headquartered? | Genomma Lab is headquartered in Mexico. |
| How many employees does Genomma Lab have? | As of today, Genomma Lab has over 1K employees. |
| Is Genomma Lab publicly listed? | Yes, Genomma Lab is a public company listed on Bolsa Mexicana de Valores. |
| What is the stock symbol of Genomma Lab? | Genomma Lab trades under LABB ticker. |
| When did Genomma Lab go public? | Genomma Lab went public in 2008. |
| Who are competitors of Genomma Lab? | Genomma Lab main competitors are Procter & Gamble Health, Sido Muncul, Mega Lifesciences, Jamieson Wellness. |
| What is the current market cap of Genomma Lab? | Genomma Lab's current market cap is $953M. |
| What is the current revenue of Genomma Lab? | Genomma Lab's last 12 months revenue is $1B. |
| What is the current revenue growth of Genomma Lab? | Genomma Lab revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Genomma Lab? | Current revenue multiple of Genomma Lab is 1.2x. |
| Is Genomma Lab profitable? | Yes, Genomma Lab is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genomma Lab? | Genomma Lab's last 12 months EBITDA is $241M. |
| What is Genomma Lab's EBITDA margin? | Genomma Lab's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Genomma Lab? | Current EBITDA multiple of Genomma Lab is 5.1x. |
| What is the current FCF of Genomma Lab? | Genomma Lab's last 12 months FCF is $73M. |
| What is Genomma Lab's FCF margin? | Genomma Lab's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Genomma Lab? | Current FCF multiple of Genomma Lab is 16.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.